Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 18/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515082 | 0.89 | EGFR (0.54) | TYK2EGFRJAK2JAK1 | |
| SCHEMBL3514216 | 0.89 | TYK2 (0.56) | TYK2EGFRJAK2JAK1CDK9 | |
| SCHEMBL3512664 | 0.88 | EGFR (0.55) | TYK2EGFRJAK2JAK1CDK9 | |
| SCHEMBL3516334 | 0.88 | EGFR (0.55) | TYK2EGFRJAK2JAK1 | |
| SCHEMBL13043669 | 0.88 | EGFR (0.53) | TYK2EGFRJAK2JAK1 | |
| SCHEMBL3514949 | 0.87 | TYK2 (0.63) | TYK2EGFRJAK2JAK1 | |
| SCHEMBL3514346 | 0.87 | TYK2 (0.49) | TYK2EGFRJAK2JAK1CDK9 | |
| SCHEMBL3514089 | 0.86 | EGFR (0.53) | TYK2EGFRJAK2JAK1CDK9 | |
| SCHEMBL3513079 | 0.86 | TYK2 (0.51) | TYK2EGFRJAK2CDK2KDR | |
| SCHEMBL3514091 | 0.86 | TYK2 (0.49) | TYK2EGFRJAK2JAK1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | TYK2 21/4885EGFR 212/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.